Investor Presentaiton
Research and Development
Development Pipeline (as of May 15, 2023)
|: Psychiatry & Neurology
Area
Japan
U.S.
: Oncology : Others
DSP-9632P
Phase 1
(Levodopa-induced dyskinesia
in Parkinson's disease)
DSP-0187
(Narcolepsy)
DSP-0378
(Dravet syndrome, Lennox-
Gastaut syndrome)
DSP-3905
(Neuropathic pain)
SEP-378614
(To be determined)
SEP-380135
(To be determined)
DSP-0038
(Alzheimer's disease psychosis)
DSP-3456
(Treatment resistant
depression)
DSP-2342
(To be determined)
TP-3654
(Myelofibrosis)
DSP-5336
(Acute leukemia)
DSP-0390
(Glioblastoma)
TP-3654
(Myelofibrosis)
DSP-5336
(Acute leukemia)
DSP-0390
(Glioblastoma)
TP-1287
(Solid tumors)
TP-1454
(Solid tumors)
KSP-1007
(Complicated urinary tract infections,
Complicated intra-abdominal infections)
SP-101
(cystic fibrosis)
Phase 2
EPI-589
(ALS/Investigator-initiated study)
Allo iPS cell-derived products
(Parkinson's disease/
Investigator-initiated study)
EPI-589
(Parkinson's disease/ALS)
ulotaront (SEP-363856)
(Parkinson's disease psychosis)
rodatristat ethyl
(Pulmonary arterial hypertension)
URO-902
(Overactive bladder)
Revisions since the announcement of January 2023 are shown in red
Phase 3
ulotaront (SEP-363856)
(Schizophrenia)
ulotaront (SEP-363856)
(Generalized anxiety disorder)*
SEP-4199
(Bipolar I depression)
ulotaront (SEP-363856)
(Schizophrenia)
ulotaront (SEP-363856)
(Adjunctive major depressive
disorder)*
ulotaront (SEP-363856)
(Generalized anxiety disorder)*
SEP-4199
(Bipolar I depression)
GEMTESAⓇ (vibegron)
(New indication: OAB in men
with BPH)
NDA submitted
China
ulotaront (SEP-363856)
(Schizophrenia)
vibegron
(Overactive bladder)
*Phase 2/3 study
lefamulin
(Bacterial community-acquired pneumonia)
© Sumitomo Pharma Co., Ltd. All Rights Reserved. 16View entire presentation